Pyrimidine compounds for the treatment of cancer
Described are compounds of Formula I or Formula II: wherein: ring A is a 5- or 6-membered heteroaryl group; dashed lines are optional double bonds; X is N or O; Y is a carbon atom or an S or N heteroatom in ring A in any suitable location; and substituents are as given herein. Compositions containing the same and methods of using the same in treating cancers such as acute lymphoblastic leukemia are also described.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. A composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.
3. The compound of claim 1 wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 wherein the compound is:
or a pharmaceutically acceptable salt thereof.
6. A compound having the following structure:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 wherein the compound is:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 wherein the compound is:
or a pharmaceutically acceptable salt thereof.
9. A compound of Formula IIa:
wherein:
R 1 is —R 5 R 6 , where R 5 is C1to C3 alkyl and R 6 is piperidyl unsubstituted or substituted from 1 to 3 times with sulfono, halo, amino, nitro, alkyl, alkoxyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R 2 is:
where X is OH and n is 0;
wherein R 3 is C1-C8 alkyl,
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9 , wherein R 6 is piperidyl which is substituted from 1 to 3 times with sulfono, halo, amino, nitro, alkyl, alkoxyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
11. The compound of claim 9 , wherein R 5 is —CH 2 —.